PETER FEINSTEIN co-founded BioVentures Investors in 1997 and has
been a General Partner of Fund I since its inception. In 1987 he
founded Feinstein Kean Partners Inc., now known as Feinstein Kean
Healthcare (‘FKH’), in Cambridge, Massachusetts. FKH is a leading
biotechnology communications and strategic consulting firm.
Together with its subsidiary, Kendall Strategies, FKH provides
business development and strategic planning, investor relations,
scientific communications and product marketing services to
biotechnology companies. In 1999, Mr. Feinstein and his partners
sold the business to an affiliate of WPP Group, the world’s
largest communications and advertising company. Mr. Feinstein has
been an advisor in numerous life science company IPOs, private
placements, limited partnerships, corporate repositionings,
mergers and startups. Mr. Feinstein pioneered the approach of
establishing valuation prior to product sales through scientific
and business achievements and is experienced in establishing
biotechnology valuation and financing. In 1982 Mr. Feinstein was
hired by Dr. Gilbert to serve as Vice President, Corporate
Communications at Biogen N.V. From 1982 to 1987, his
responsibilities at Biogen included investor relations and press
relations programs in Europe and in the US, and all other
corporate communications activities for this leading
international biotechnology company. Earlier, from 1980 to 1982,
Mr. Feinstein was Vice President at Newsome & Co., Inc., New
England’s largest public relations agency, where he created and
implemented corporate communications projects and programs for
clients including Biogen, General Electric, IBM, Raytheon, and
Coopers & Lybrand. Mr. Feinstein was a co-Founder and served as a
Director of the Massachusetts Biotechnology Council from its
inception in 1985 until 1997. He was a member of the Governor’s
Task Force, Subcommittee on Biotechnology and Pharmaceutical
Development, and has produced numerous industry surveys and
reports. Mr. Feinstein earned his BA from New York University in
1969.
Peter Feinstein - Bioventures Investors
May 13, 2003